Faculty profile

Sebastien Perreault

ResearcherPediatricsUniversité de Montréal

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université de Montréal directory, so their courses may be missing. Find their university profile.

Sebastien Perreault

Researcher

Pediatrics

Health Sciences

Université de Montréal

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
13 publications in the last five years, latest in 2026.
Senior (last) author on 2 recent papers, a sign of leading a research group.
Principal investigator on 2 research grants (2 CIHR), most recently in 2022.
Supervisor on 1 trainee award (1 CIHR), most recently in 2024.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Clinical Trial

Latest papers

A multi-institutional report of children with atypical teratoid rhabdoid tumor treated with intensive multimodal therapy.
Neuro-oncology practice · 2026
Paroxysmal Dyskinesia with a Novel Variant in the Histone 3 Family 3B (H3-3B) Gene.
Movement disorders clinical practice · 2026
Point/counterpoint: Upfront BRAF inhibition for adult BRAF-mutant high-grade gliomas.
Neuro-oncology · 2025 · first author

All 23 publications

Latest funding

PARTNR Study (Pediatric, Adolescent and young adult Response to Targeted agents Registry)
CIHR · 2024 · Supervisor
$6,000
A phase 2 study of mirdametinib and vinblastine for newly diagnosed or previously untreated patients with pediatric low-grade glioma and activation of the MAPK pathway
CIHR · 2022 · Nominated PI
$463,500
A Phase 2 study of Trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathwa
CIHR · 2019 · Nominated PI
$573,750

All 4 grants and awards

23 publications.

A multi-institutional report of children with atypical teratoid rhabdoid tumor treated with intensive multimodal therapy.

Margol AS, Hoffman LM, Ronsley R, Tran J, Malvar J, Chi YY, Leary S, Stevens J, Faulk KE, Salloum R, Hutchins SC, Wu C, Smiley NP, Aguilar A, Martinez M, Lafay-Cousin L, Abdelbaki MS, Cluster A, Perreault S, Gilheeney S, Szalontay L, Reddy AT, Dhall G

Neuro-oncology practice2026

DOI: 10.1093/nop/npag014 PMID: 42453193

Paroxysmal Dyskinesia with a Novel Variant in the Histone 3 Family 3B (H3-3B) Gene.

D'Onofrio G, Perreault S, Mitchell G, Meijer IA

Movement disorders clinical practice2026

DOI: 10.1002/mdc3.70236 PMID: 40696776

Point/counterpoint: Upfront BRAF inhibition for adult BRAF-mutant high-grade gliomas.

Perreault S, Geurts M, Mahdi J, Schreck KC, Preusser M, Wen PY, Lim-Fat MJ, Werner JM

Neuro-oncology2025First author

DOI: 10.1093/neuonc/noaf164 PMID: 40717628

Germline analysis of an international cohort of pediatric diffuse midline glioma patients.

Mateos MK, Ajuyah P, Fuentes-Bolanos N, El-Kamand S, Barahona P, Altekoester AK, Mayoh C, Holliday H, Liu J, Cui L, Pfaff E, Mackay A, Resnick AC, Pinese M, Lau LMS, Khuong-Quang DA, Dias K, Goudie C, Salkeld A, Rokita JL, Jones DTW, Juretic N, Hayden E, Pfister SM, Kramm CM, Blattner-Johnson M, Jabado N, Tsoli M, Vittorio O, Mueller S, Guo Y, Tucker K, Waszak SM, Perreault S, Jones C, Wong-Erasmus M, Cowley MJ, Ziegler DS

Neuro-oncology2025

DOI: 10.1093/neuonc/noaf061 PMID: 40072012

Disseminated DIG-DIA With a Rare FMR1-RAF1 Fusion With Good Response to Targeted Therapy.

Reeves-Breton L, Allain L, Sathyakumar S, Boyer E, Crevier L, Perreault S, Richer M, Bourget C, Giannakouros P, LeGallou W, Faury D, Laflamme J, Hawkins C, Bouffet E, Jabado N, Coltin H, Renzi S

Pediatric blood & cancer2025

DOI: 10.1002/pbc.31454 PMID: 39558821

An international study presenting a federated learning AI platform for pediatric brain tumors.

Lee EH, Han M, Wright J, Kuwabara M, Mevorach J, Fu G, Choudhury O, Ratan U, Zhang M, Wagner MW, Goetti R, Toescu S, Perreault S, Dogan H, Altinmakas E, Mohammadzadeh M, Szymanski KA, Campen CJ, Lai H, Eghbal A, Radmanesh A, Mankad K, Aquilina K, Said M, Vossough A, Oztekin O, Ertl-Wagner B, Poussaint T, Thompson EM, Ho CY, Jaju A, Curran J, Ramaswamy V, Cheshier SH, Grant GA, Wong SS, Moseley ME, Lober RM, Wilms M, Forkert ND, Vitanza NA, Miller JH, Prolo LM, Yeom KW

Nature communications2024

DOI: 10.1038/s41467-024-51172-5 PMID: 39223133

Epidemiology of Pediatric Tumors in Quebec: A 17-Year Report of Cancer in Young People in the Canada Registry.

Bellavance C, Lalonde B, Simonyan D, Jabado N, Perreault S, Larouche V

Current oncology (Toronto, Ont.)2024

DOI: 10.3390/curroncol31050204 PMID: 38785485

Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study.

Ercan AB, Aronson M, Fernandez NR, Chang Y, Levine A, Liu ZA, Negm L, Edwards M, Bianchi V, Stengs L, Chung J, Al-Battashi A, Reschke A, Lion A, Ahmad A, Lassaletta A, Reddy AT, Al-Darraji AF, Shah AC, Van Damme A, Bendel A, Rashid A, Margol AS, Kelly BL, Pencheva B, Heald B, Lemieux-Anglin B, Crooks B, Koschmann C, Gilpin C, Porter CC, Gass D, Samuel D, Ziegler DS, Blumenthal DT, Kuo DJ, Hamideh D, Basel D, Khuong-Quang DA, Stearns D, Opocher E, Carceller F, Baris Feldman H, Toledano H, Winer I, Scheers I, Fedorakova I, Su JM, Vengoechea J, Sterba J, Knipstein J, Hansford JR, Gonzales-Santos JR, Bhatia K, Bielamowicz KJ, Minhas K, Nichols KE, Cole KA, Penney L, Hjort MA, Sabel M, Gil-da-Costa MJ, Murray MJ, Miller M, Blundell ML, Massimino M, Al-Hussaini M, Al-Jadiry MF, Comito MA, Osborn M, Link MP, Zapotocky M, Ghalibafian M, Shaheen N, Mushtaq N, Waespe N, Hijiya N, Fuentes-Bolanos N, Ahmad O, Chamdine O, Roy P, Pichurin PN, Nyman P, Pearlman R, Auer RC, Sukumaran RK, Kebudi R, Dvir R, Raphael R, Elhasid R, McGee RB, Chami R, Noss R, Tanaka R, Raskin S, Sen S, Lindhorst S, Perreault S, Caspi S, Riaz S, Constantini S, Albert S, Chaleff S, Bielack S, Chiaravalli S, Cramer SL, Roy S, Cahn S, Penna S, Hamid SA, Ghafoor T, Imam U, Larouche V, Magimairajan Issai V, Foulkes WD, Lee YY, Nathan PC, Maruvka YE, Greer MC, Durno C, Shlien A, Ertl-Wagner B, Villani A, Malkin D, Hawkins C, Bouffet E, Das A, Tabori U

The Lancet. Oncology2024

DOI: 10.1016/s1470-2045(24)00026-3 PMID: 38552658

Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti-PD-1 Monotherapy: A Report from the International RRD Consortium.

Das A, Fernandez NR, Levine A, Bianchi V, Stengs LK, Chung J, Negm L, Dimayacyac JR, Chang Y, Nobre L, Ercan AB, Sanchez-Ramirez S, Sudhaman S, Edwards M, Larouche V, Samuel D, Van Damme A, Gass D, Ziegler DS, Bielack SS, Koschmann C, Zelcer S, Yalon-Oren M, Campino GA, Sarosiek T, Nichols KE, Loret De Mola R, Bielamowicz K, Sabel M, Frojd CA, Wood MD, Glover JM, Lee YY, Vanan M, Adamski JK, Perreault S, Chamdine O, Hjort MA, Zapotocky M, Carceller F, Wright E, Fedorakova I, Lossos A, Tanaka R, Osborn M, Blumenthal DT, Aronson M, Bartels U, Huang A, Ramaswamy V, Malkin D, Shlien A, Villani A, Dirks PB, Pugh TJ, Getz G, Maruvka YE, Tsang DS, Ertl-Wagner B, Hawkins C, Bouffet E, Morgenstern DA, Tabori U

Cancer discovery2024

DOI: 10.1158/2159-8290.cd-23-0559 PMID: 37823831

Treatment of Refractory Epilepsy With MEK Inhibitor in Patients With RASopathy.

D'Onofrio G, Delrue MA, Lortie A, Marquis C, Striano P, Jaworski M, Andelfinger G, Perreault S

Pediatric neurology2023Senior author

DOI: 10.1016/j.pediatrneurol.2023.08.019 PMID: 37722300

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2022

Subject: Prospective PhD student: Clinical Trial Dear Professor Perreault, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "A multi-institutional report of children with atypical teratoid rhabdoid tumor treated with intensive multimodal therapy." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "A phase 2 study of mirdametinib and vinblastine for newly diagnosed or previously untreated patients with pediatric low-grade glioma and activation of the MAPK pathway" (2022), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Sebastien Perreault

Research

Latest papers

Latest funding

A multi-institutional report of children with atypical teratoid rhabdoid tumor treated with intensive multimodal therapy.

Paroxysmal Dyskinesia with a Novel Variant in the Histone 3 Family 3B (H3-3B) Gene.

Point/counterpoint: Upfront BRAF inhibition for adult BRAF-mutant high-grade gliomas.

Germline analysis of an international cohort of pediatric diffuse midline glioma patients.

Disseminated DIG-DIA With a Rare FMR1-RAF1 Fusion With Good Response to Targeted Therapy.

An international study presenting a federated learning AI platform for pediatric brain tumors.

Epidemiology of Pediatric Tumors in Quebec: A 17-Year Report of Cancer in Young People in the Canada Registry.

Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study.

Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti-PD-1 Monotherapy: A Report from the International RRD Consortium.

Treatment of Refractory Epilepsy With MEK Inhibitor in Patients With RASopathy.

PARTNR Study (Pediatric, Adolescent and young adult Response to Targeted agents Registry)

A phase 2 study of mirdametinib and vinblastine for newly diagnosed or previously untreated patients with pediatric low-grade glioma and activation of the MAPK pathway

A Phase 2 study of Trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathwa

Combined MEK inhibition and metronomic chemotherapy for recurrent/refractory paediatric low grade gliomas

Frequent collaborators

Nada Jabado

Eric Bouffet

Cynthia Hawkins

Vijay Ramaswamy

Uri Tabori

Birgit Ertl-Wagner

Birgit Ertl-Wagner

Ute Bartels

Valérie Larouche

Philippe Major

Adam Shlien

Ala Birca

David Malkin

Sonia Cellot

Daniel Sinnett

Abhaya Kulkarni

Livia Garzia

Livia Garzia

Catherine Goudie

Annie Huang

Lionel Carmant

James Drake

Mathieu Blanchette

Gregor Andelfinger

Adam Fleming

Sunit Das

Elsa Rossignol